GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

BIO CEO & Investor Conference Format: "IPO Class of 2024 Panel" and one-on-one meetings Date: February 10, 2025 Location: New York, NY Registered conference attendees may schedule one-on-one meetings ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI ... gaps in current therapies Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers ...

GSK is doling out $1 billion in cash for the ... from which IDRx licensed it in 2022. The tyrosine kinase inhibitor (TKI) is designed to be a first- and second-line therapy for gastrointestinal ...